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Introduction: This study investigates the role of Toll-like receptor 2 (TLR2) in the regulation of migratory and invasive
mechanisms in rheumatoid arthritis (RA).
Methods: Invasion, migration, matrix metalloproteinase (MMP)-1, -3 and tissue inhibitor of matrix metalloproteinase-3
(TIMP-3) expression, β-integrin binding, cytoskeletal rearrangement and Ras-related C3 botulinum toxin substrate 1 (Rac1)
activation in response to a TLR2-ligand, Pam3CSK4 (1 μg/ml), in ex vivo RA synovial tissue explants, primary RA
synovial fibroblasts (RASFC) and microvascular endothelial cells (HMVEC) were assessed by Transwell Matrigel™
invasion chambers, enzyme-linked immunosorbent assay (ELISA), multiplex adhesion binding assay, reverse
transcription polymerase chain reaction (RT-PCR), F-actin immunofluorescent staining, matrigel synovial outgrowths,
Rac1 pull-down assays/Western blot and zymography. β1-integrin expression in RA/control synovial tissue was assessed
by immunohistology. The effect of Pam3CSK4 on cell migration, invasion, MMP-3 and Rac1 activation was examined in
the presence or absence of anti-β1-integrin (10 μg/ml) or anti-IgG control (10 μg/ml). The effect of an anti-TLR-2 mAb
(OPN301)(1 μg/ml) or immunoglobulin G (IgG) control (1 μg/ml) on RASFC migration and RA synovial tissue MMP activity
was assessed by wound assays, ELISA and zymography.
Results: Pam3CSK4 significantly induced cell migration, invasion, MMP-1, MMP-3, MMP-2 and MMP-9 expression
and induced the MMP-1/TIMP-3 and MMP-3/TIMP-3 ratio in RASFC and explants (p <0.05). β1-integrin expression was
significantly higher in RA synovial tissue compared to controls (p <0.05). Pam3CSK4 specifically induced β1-integrin
binding in RASFC (p <0.05), with no effect observed for β2-4, β6, αvβ5 or α5β1. Pam3CSK4 increased β1-integrin mRNA
expression, Rac1 activation, RASFC outgrowths and altered cytoskeletal dynamic through induction of filopodia
formation. Pam3CSK4-regulated cell migration and invasion processes, but not MMP-3, were inhibited in the
presence of anti-β1-integrin (p <0.05), with no effect observed for anti-IgG control. Furthermore, anti-β1-integrin inhibited
Pam3CSK4-induced Rac1 activation. Finally, blockade of TLR2 with OPN301 significantly decreased spontaneous release of
MMP-3, MMP-2 and MMP-9 and increased TIMP-3 secretion from RA synovial explant cultures (p <0.05). Incubation of
RASFC with OPN301 RA ex vivo conditioned media inhibited migration and invasion compared to IgG control.
Conclusions: TLR2 activation induces migrational and invasive mechanisms, which are critically involved in the
pathogenesis of RA, suggesting TLR2 as a potential therapeutic target for the treatment of RA.Introduction
Rheumatoid arthritis (RA) is a chronic progressive auto-
immune disease, characterised by synovial proliferation,
neovascularisation and leucocyte extravasation, joint de-
struction and functional disability. RA synoviocytes mani-
fest an abnormal phenotype with increased proliferation,
resistance to apoptosis and invasiveness of adjacent tissue* Correspondence: ursula.fearon@ucd.ie
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(http://creativecommons.org/publicdomain/zero[1–3]. This results in synoviocyte hyperplasia, which trans-
forms the synovial membrane (SM) into an aggressive,
tumour-like tissue ‘pannus’, which is capable of destroying
adjacent articular cartilage and bone.
Toll-like receptors (TLRs) have been implicated in the
pathogenesis of RA with studies showing increased TLR2
and TLR4 expression in the perivascular regions of the
joint, [4] at the sites of attachment and invasion into cartil-
age/bone, and on synovial macrophages [5]. Bacterial pep-
tidoglycan (PG), a TLR2 ligand, has been detected in RA
synovial fluids [6]. Increased expression of TLR2 has beenarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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cal cell wall (SCW)-induced arthritis does not develop in
TLR2-deficient mice [7]. Furthermore, studies have demon-
strated that dominant negative forms of the TLR2 adapter
molecules myeloid differentiation primary response gene 88
(MyD88) and MAL/TIRAP inhibit pro-inflammatory
cytokine production in RA synoviocytes [8]. Recent
data has shown that the pattern-recognition receptor
nucleotide-binding oligomerisation domain-containing
protein 1 (NOD1) synergises with TLR2 in the induction of
cytokines in RA synovial fibroblast cells (RASFC) [9].
TLR2-induced cytokine expression has also been shown to
be mediated by miR-19 in RASFC [10]. Furthermore, stud-
ies have shown the involvement of the Tie-2 receptor in
mediating TLR2-induced angiogenesis [11]. Together these
studies suggest that TLR2 is a key mediator involved in
promoting cell migrational, invasive and destructive mecha-
nisms in the RA joint.
Cell migration is essential for tissue infiltration during
the inflammatory process and is initiated by cell polar-
isation and the formation of membrane protrusions at
the leading edge [12]. Integrin-linked activation of the
small guanosine triphosphates (GTPases) of the Rho
family (Cdc42, Rho and Rac1) mediates cytoskeletal dy-
namics such as filopodia and lamellipodia formation and
stress fibre formation, which is essential for cell migration
[13, 14]. Integrin-linked activation of Rho GTPases medi-
ates gene transcription, cell cycle progression and adhesion
[13, 15]. Previous studies have demonstrated that integrin
blockade can inhibit fibroblast invasion and adhesion of
cells to the extracellular matrix (ECM) [16, 17]. In particu-
lar, blockade of α2β1 integrin in RA protects against cartil-
age destruction via reduction of matrix metalloproteinase
(MMP)-3 [18]. In this study we investigate the effect of
TLR2 on migrational and invasive mechanisms in RA. We
demonstrate that activation of TLR2 induces RASFC mi-
gration, invasion and induction of MMPs. Furthermore, we
show that TLR2-induced migration/invasion is partly medi-
ated by β1 integrin and downstream alterations in cytoskel-
etal dynamics and Rac1 activation. Finally, using an ex vivo
RA synovial explant model and RASFC, we demonstrated
that an anti-TLR2 antibody (OPN301) significantly inhib-
ited MMP expression and migration. Together this study
further demonstrates that TLR2 activation plays a key role
in regulating invasive mechanisms in RA, a key process in-
volved in the pathogenesis of RA.
Materials and methods
Patients and RA synovial tissue
Patients with RA were recruited from the outpatient
clinics at the Department of Rheumatology, St. Vincent’s
University Hospital (SVUH). Only patients with an ac-
tively inflamed knee joint and fulfilling the revised
American College of Rheumatology criteria were recruited[19]. RA synovial tissue was obtained at arthroscopy under
direct visualisation as previously described [20]. Normal
synovial tissue was obtained from ten patients (eight men;
two women) undergoing interventional arthroscopy for
cruciate ligament tears. Fully informed written consent was
obtained from each patient prior to inclusion. This study
was approved by the SVUH Ethics and Medical Research
Committee.
Immunohistochemistry
Synovial biopsies obtained at arthroscopy were snap frozen
in OCT compound and stored at −80 °C. Seven-micron-
thick sections were cut using a cryostat and placed on glass
slides coated with 2 % 3-amino-propyl-triethoxy-silane
(Sigma-Aldrich Ireland Ltd, Dublin, Ireland), dried over-
night at room temperature and stored at −80 °C. To exam-
ine β1-integrin expression and localised distribution in the
synovium, immunohistochemical analysis was performed in
RA (n = 17) and normal synovial tissue (n = 9). Tissue
sections were fixed in acetone for 10 min and air-dried.
Non-specific binding was blocked using 10 % casein
buffer. A routine three-stage immunoperoxidase labelling
technique incorporating avidin-biotin-immunoperoxidase
complex (Dako, Glostrup, Denmark) was used. Sections
were incubated with mouse polyclonal anti-β1-integrin
(R&D Systems, Cambridge, UK) at room temperature for
1 h. Sections were also incubated with an appropriate
isotype-matched mouse-immunoglobulin G (IgG) control
antibody (R&D Systems, Cambridge, UK) as negative
controls. Colour was developed in solution containing
diaminobenzadine-tetrahydrochloride (Sigma-Aldrich),
0.5 % H2O2 in phosphate-buffered saline (PBS) buffer
(pH 7.6). Slides were counterstained with haematoxylin
(BDH Laboratory Supplies, Poole, UK) and hydration
and fixation was performed through a series of IMS and
xylene solutions. Sections were mounted using DPX
mountant (BDH Laboratory Supplies). Images were cap-
tured using Olympus DP50 light microscope and analysis
software (Soft Imaging System Corporation, Lakewood,
CO, USA). Slides were analysed using a well-established
semi-quantitative scoring method (0–4) and scored separ-
ately for perivascular/vascular, lining layer and sub-lining
layer regions [21].
Ex vivo synovial explants
RA synovial biopsies taken at the time of arthroscopies
were sectioned into two equal pieces and cultured in 96-
well plates in full RPMI medium. This culture models
maintains the synovial architecture and cell–cell contact,
and therefore more closely reflects the in vivo environment.
For stimulation experiments, RA synovial biopsies were
cultured with Pam3CSK4 (1 μg/ml) or basal control media
for 24 h. For blockade experiments, biopsies were cultured
in the presence of OPN301 (mouse IgG1 monoclonal anti-
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Dublin, Ireland, 1 μg/ml) or IgG isotype control (mouse
IgG1 isotype control, Opsona Therapeutics; 1 μg/ml). For
each experiment, three technical replicates are combined
(three individual biopsies from one patient) to give one bio-
logical sample, and this was performed on a number of dif-
ferent patients. This is important to allow for heterogeneity
within the patient joint and between patients. Following in-
cubation, culture supernatants were harvested and assayed
for MMPs by enzyme-linked immunosorbent assay (ELISA)
and zymography. For further functional experiments, 10 %
conditioned media from OPN301 or IgG1-treated ex vivo
synovial tissue was co-cultured with primary RASFC and
invasion, migration and MMP expression was assessed as
outlined below.
Isolation and culture of primary RASFC
RA synovial biopsies were digested with 1 mg/ml collage-
nase type 1 (Worthington Biochemical Corp., Freehold, NJ,
USA) in RPMI medium (Gibco-BRL, Paisley, UK) for 4 h at
37 °C in humidified air with 5 % CO2. Dissociated cells were
grown to confluence in RPMI 1640 medium, 10 % fetal calf
serum (FCS) (Gibco-BRL), 10 ml of 1 mmol/l HEPES
(Gibco-BRL), penicillin (100 units/ml; Bio-sciences Ltd.,
Dublin, Ireland), streptomycin (100 units/ml; Bio-sciences)
and fungizone (0.25 μg/ml; Bio-sciences) before passaging.
Culture of HMVEC
Human microvascular endothelial cells (HMVEC) (Lonza,
Walkersville, MD, USA) were incubated in endothelial cell
basal medium (EBM: Lonza) supplemented with endothe-
lial cell growth medium (EGM) microvascular bullet kit
containing 25 ml FCS, 0.5 ml hEGF, 0.5 ml hydrocortisone,
0.5 ml gentamicin, 0.5 ml bovine brain extract (Lonza).
Cells were grown to confluence in T75cm flasks at 37 °C in
humidified air with 5 % CO2 prior to being harvested with
trypsin-EDTA (Lonza). HMVEC between the fourth and
eight passages were used for experiments.
Ex vivo RA fibroblast outgrowths
To examine RA synovial outgrowths, an ex vivo synovial
tissue explant model was utilised [22]. A total of 50 μl of
matrigel (Bio-sciences) was added to each well of a 96-
well plate and incubated for 1 h at 37 °C. Following this,
RA synovial tissue was sectioned and placed in matrigel
wells with RPMI 1640 medium supplemented with 10 %
FCS (Gibco-BRL), 10 ml of 1 mmol/l HEPES (Gibco-BRL),
penicillin (100 units/ml; Bio-sciences), streptomycin
(100 units/ml; Bio-sciences) and fungizone (0.25 μg/ml;
Bio-sciences). RA explants were stimulated with TLR2
ligand Pam3CSK4 (1 μg/ml) over a time course of
1–15days. Supernatants were collected every 4 days and
replenished with fresh media and experimental agents.
Images were taken using a phase-contrast microscope(a Nikon TMS microscope (Nikon Corp., Tokyo, Japan)
linked to a Canon S70 camera (Canon Inc., Tokyo, Japan)).
Immunofluorescent staining for F-actin
Primary RASFC were seeded sparsely into 8-well cham-
ber slides and serum starved for 24 h and subsequently
cultured with Pam3CSK4 (1 μg/ml) for a further 24 h.
Slides were washed with PBS and fixed with 1 % parafor-
maldehyde in PBS for 20 min. To visualise F-actin, slides
were stained with Oregon Green® phalloidin (Molecular
Probes, Leiden, The Netherlands). Nuclei were counter-
stained with DAPI (Sigma-Aldrich, St. Louis, MO, USA).
Stained cells were visualised with a Leitz DM40 micro-
scope (Leica Microsystems, Wetzlar, Germany) and im-
ages were captured using the AxioCam system and
AxioVision 3.0.6. software (Carl Zeiss Inc., Thornwood,
NY, USA).
β integrin-mediated cell adhesion array
The Chemicon Integrin-Mediated Cell Adhesion Array
Kit (Chemicon International Inc., Temicula, CA, USA)
utilises monoclonal antibodies generated against human
integrins, which are immobilised onto a goat anti-mouse
antibody-coated microplate and used to capture cells ex-
pressing these integrins on their cell surface. RASFC
were grown to confluence, serum starved overnight and
then cultured with Pam3CSK4 (1 μg/ml) for an add-
itional 24 h. Single-cell suspensions were prepared using
a non-enzymatic dissociation buffer (Sigma-Aldrich). A
total of 100 μl (1 × 105 cells in adhesion buffer) was
added to each well of the Beta Integrin-Mediated Cell
Adhesion Array Kit (Chemicon). After incubation for 2
h at 37 °C/5 % CO2, wells were washed and stained, and
cell-bound stain was solubilised in extraction buffer. In-
tegrin expression was determined by measuring the ab-
sorbance at 570 nm.
Wound repair assays
RASFC and HMVEC were seeded onto 48-well plates
and grown to confluence. A single scratch wound was
induced through the middle of each well with a sterile
pipette tip. Cells were subsequently stimulated for 24 h
with Pam3CSK (1 μg/ml). RASFC and HMVEC migra-
tion across the wound margins from 12 to 24 h was
assessed and photographed using a phase-contrast
microscope (Nikon TMS microscope linked to a Canon
S70 camera). To assess if the β1-integrin signalling me-
diates Pam3CSK4-induced cell migration, experiments
were also performed in the presence or absence of anti-
β1-integrin (10 μg/ml) or isotype-matched non-immune
IgG (10 μg/ml). Semi-quantitative analysis of cell repopula-
tion of the wound was assessed by two blinded observers as
previously described [23]. Briefly, images of the scratch
wound assays were taken at x20 magnification. The mean
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average of three individual measurements from each
wound. This process was repeated for all technical repli-
cates. Measurement of scratches at time 0 were designated
as 100 % open. From this, the percentage of closure for all
scratches was calculated. Twenty-four percent wound clos-
ure represents the distance the cells migrated into the
scratch wound. Data is represented as mean ± SEM. Fur-
thermore to assess the effect of blocking TLR2 on cell mi-
gration, RASFC were incubated with 10 % conditioned
media from ex vivo RA synovial explants cultured either
with OPN301 (1 μg/ml) or IgG isotype control (1 μg/ml)
for 24 h.
Transwell migration assay
Biocoat Matrigel™ Invasion Chambers (Becton Dickinson,
Oxford, UK) were used to assess RASFC and HMVEC in-
vasion. Cells were seeded at a density of either 2.5 × 104
cells per well in the migration chamber on 8 μm mem-
branes pre-coated with matrigel. Cells were incubated for
either 24 h (HMVEC) or 48 h (RASFC). Initial experiments
assessed the effect of Pam3CSK4 (1 μg/ml) on HMVEC
and RASFC invasion. To assess if the β1-integrin signalling
pathways mediate Pam3CSK4-induced cell invasion, experi-
ments were also performed in the presence or absence of
anti-β1-integrin (10 μg/ml) or isotype-matched non-
immune IgG (10 μg/ml). To determine if TLR2 blockade
could further inhibit invasion, RASFC were cultured in
the presence of 10 % RA ex vivo explant-conditioned
media previously cultured with either anti-TLR2 antibody
OPN301(1 μg/ml) or IgG control (1 μg/ml). Non-migrating
RASFC and HMVEC were removed from the upper surface
by gentle scrubbing. Migrating cells attached to the lower
membrane were fixed with 1 % glutaraldehyde and stained
with 0.1 % crystal violet. Cells from five random high-
power fields for each well were counted to assess the aver-
age number of migrating cells [24].
Rac1 pull-down assay
Rac1 activity was determined using an Active Rac1 Pull-
Down Detection Kit (Thermo Scientific, Pierce, Rockford,
IL, USA) as per the manufacturer’s protocol. RASFC were
stimulated with Pam3CSK4 (1 μg/ml) for 12 h. After treat-
ment, cells were rinsed once with ice-cold PBS and scraped
into 500 μl of lysis buffer. Samples were vortexed and cen-
trifuged at 16,000 g for 15 min at 4 °C and the supernatant
was transferred to a new tube. Active Rac1 was then affinity
purified with GST-Pak-PBD (Pak 1-p21-binding domain),
separated by SDS-PAGE and measured by Western blotting
using anti-Rac1 antibodies and total Rac1 protein. To assess
if the β1-integrin signalling pathways mediate Pam3CSK4-
induced Rac1 activation, experiments were also performed
in the presence or absence of anti-β1-integrin (10 μg/ml) or
isotype-matched non-immune IgG (10 μg/ml). The signalintensity of the appropriate bands on the autoradiogram
was calculated using the Kodak EDAS 120 System (Kodak,
Rochester, NY, USA). Densitometry analysis performed out
using ImageJ software. Data is expressed as fold change
compared to β-actin control.
Matrix metalloproteinase expression
RASFC were seeded in 48-well plates containing RPMI
plus supplements for 24 h. Following 24 h of incubation
in serum-free RPMI 1640, cells were stimulated with
Pam3CSK4 (1 μg/ml), experiments were also performed
in the presence or absence of anti-β1-integrin (10 μg/ml) or
isotype-matched non-immune IgG (10 μg/ml). For inhibi-
tory experiments, RA ex vivo biopsies were treated as out-
lined above. Supernatants were harvested and levels of
MMP-3, MMP-1 and tissue inhibitor of matrix metallo-
proteinase (TIMP)-3 were measured by specific ELISA
(R&D Systems) according to the manufacturer’s condi-
tions. The ELISA standard ranges were 10 ng/ml to
0.156 ng/ml for MMP-3 and MMP-1 and 4,000 pg/ml
to 62.5 pg/ml for TIMP-3.
Gelatin zymography
The activity of MMP-2 and MMP-9 secreted by ex vivo
RA explants and RASFC was determined by gelatin
zymography [25]. Following incubation, 10 μl super-
natant was loaded into appropriate gel lanes. Zymogram
gels consist of 7.5 % polyacrylaminde gels polymerised
together with gelatin (1 mg/ml). Following electrophor-
esis, gels were washed with 2.5 % Triton X-100 and in-
cubated with substrate buffer (50 mM Tris, 5 mM
CaCl2, pH 7.5) at 37C for 24 h. Gels were then stained
with Coolmassie brilliant blue R250 and destained with
water. Bands were identified using gelatinase standards
(Merck Millipore, Billerica, MA, USA).
mRNA extraction and PCR analysis
RASFC were grown to confluence, cultured in serum-
free RPMI medium for 24 h and then stimulated with
Pam3CSK4 (1 μg/ml) for a further 24 h. Experiments
were also performed in the presence or absence of anti-
β1-integrin (10 μg/ml) or isotype-matched non-immune
IgG (10 μg/ml). Total RNA was isolated using RNeasy
Mini Kit (Qiagen, Venlo, The Netherlands) according to
the manufacturer’s specifications. Purity of RNA was
measured and samples with a ratio over 1.8 (260:280 nm)
were used in subsequent experiments. Total RNA (200 ng)
was reverse transcribed to cDNA. Relative quantifica-
tion of gene expression was analysed with pre-optimised
conditions using Lightcycler-480 PCR technology (Roche
Diagnostics, Lewes, UK). Specific primers for β1-integrin
(Hs00559595_m1) were used and primers for 18S
(Hs99999901_sl) ribosomal RNA were used as an endogen-
ous control (Applied Biosystems, Carlsbad, CA, USA).
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SPSS 15.0 system (SPSS Inc, Chicago, IL, USA) for Win-
dows was used for statistical analysis. Wilcoxon signed-
rank test or Mann-Whitney was used for analysis of
non-parametric data. Student t test was used for paramet-
ric data. p values of less than 0.05 (*p <0.05) were deter-
mined as statistically significant. All data is represented as
mean ± SEM.
Results
TLR2 induces cell migration in RASFC and HMVEC
RASFC and HMVEC monolayers were wounded and stim-
ulated in the presence or absence of Pam3CSK4 (1 μg/ml).
Figure 1i shows representative images of wound repair in
response to Pam3CSK4 for RASFC and HMVEC, where
repopulation of wound margins was observed. Semi-
quantitative analysis demonstrated a significant increase in
cell migration in response to Pam3CSK4 (Fig. 1ii).
TLR2 induces cell invasion in RASFC and HMVEC
To assess the effects of Pam3CSK4 on RASFC and
HMVEC invasion, Transwell Matrigel™ invasion cham-
bers were utilised. Representative images of increased
RASFC and HMVEC invasion following Pam3CSK4
stimulation are shown in Fig. 2a (i). Quantitatively,
RASFC and HMVEC invasion were significantly induced
by Pam3CSK4 compared to control (p <0.05) (Fig. 2a (ii)).
To further assess the invasive microenvironment, MMP-1,
MMP-3 and TIMP-3 expression in RASFC and RA ex vivo
synovial explants were measured by ELISA. Following
Pam3CSK4 stimulation, MMP-1 expression increased
2.4-fold (basal 10.93 ng/mL compared to Pam3CSK4
25.76 ng/mL, p = 0.054) in RASFC and 1.6-fold in RA
synovial tissue (basal 81 ng/mL compared to Pam3CSK4
126.3 ng/mL, p <0.05) (Fig. 2b, 2c (i)). MMP-3 expression
increased 2.7-fold (basal 7.87 ng/mL compared to
Pam3CSK4 21.16 ng/mL) in RASFC and 1.9-fold in RAFig. 1 Representative photomicrograph demonstrating cells repopulating the w
graph quantifying RASFC and HMVEC (both n = 4) 24 h migration in response t
different to control. HMVEC human microvascular endothelial cells, RASFC rheumsynovial tissue (basal 895 ng/mL compared to Pam3CSK4
1675 ng/mL, p <0.05) (Fig. 2b, 2c (ii)). TIMP-3 secretion
from RA ex vivo explants significantly decreased 2.4-fold
(basal 21 ng/mL compared to Pam3CSK4 8.6 ng/mL,
p <0.05) (Fig. 2c (iii)), with no significant change observed
in RASFC (p = 0.09) (Fig. 2b (iii)). There was an increase in
the ratio of MMPs to TIMP-3 in both RASFC and RA
ex vivo explants. The MMP-1:TIMP-3 ratio was increased
3.7-fold in RASFC (3.9 to 14.5, p = 0.07) and 1.8-fold in RA
ex vivo biopsies (57 to 103, p <0.05) (Fig. 2b, 2c (iv)). The
MMP-3:TIMP-3 ratio also increased 2.9-fold in RASFC
(0.15 to 0.44, p <0.05) and 5.2-fold in ex vivo RA synovial
explants (41 to 215, p <0.01) (Fig. 2b, 2c (v)). Furthermore,
MMP-9 was induced in both RASFC (Fig. 2d (i)) and RA
synovial tissue (Fig. 2d (ii)) with an increase in MMP-2 ob-
served in RA explants (Fig. 2d (ii)) following Pam3CSK4 ac-
tivation as assessed by gelatin zymography.
Pam3CSK4 induces ex vivo fibroblast outgrowth and
cytoskeletal rearrangement
To further probe the effects of TLR2 activation on cell mi-
gration/invasion the effect of Pam3CSK4 on cytoskeletal
dynamics was examined using F-actin staining. Figure 3a,
in panels (i–iii), under basal or resting conditions, intact
bundles of stress fibres are clearly visible and are orientated
along the cells in a uni-directional manner. This is indi-
cated in Fig. 3a (i) and (ii) by red arrows. Figure 3a panels
(iv–vi) demonstrate the effects of Pam3CSK4 on the
F-actin cytoskeletal architecture and cell shape. Pam3CSK4
has a dramatic effect on the architecture of the cell. It in-
duces thin actin-rich extensions of the cytoplasm and
membrane ruffling (observed in Fig. 3a (iv)), indicated by
white arrows). It also induces filopodial and lamellipodial-
like structures (observed in Fig. 3a (v)), indicated by white
arrows). Lower magnification images (x40) depicted in
Fig. 3a capture cells either under basal (iii) or Pam3CSK4-
induced (vi) conditions, where these key cellular changesound in response to Pam3CSK4 (1 μg/ml) in RASFC and HMVEC (i). Bar
o Pam3CSK4 (ii). Data is represented as mean ± SEM, *p <0.05, significantly
atoid arthritis synovial fibroblast cells
Fig. 2 a (i) Representative images of Pam3CSK4 induces HMVEC and RASFC invasion compared to basal control. Following 24 h stimulation, invading cells
attached to lower membrane were fixed (1 % glutaraldehyde) and stained (0.1 % crystal violet) (mag x40). (ii) Quantification of HMVEC (n = 4) and RASFC
(n = 6) invasion. Quantification of RASFC (b) and RA synovial explant (c) MMP-1 (i), MMP-3 (ii) and TIMP-3 (iii) secretion and MMP-1/TIMP-3 (iv) and MMP-3/
TIMP-3 ratio (v) following Pam3CSK4 stimulation (n = 7). d shows representative zymogram for pro-MMP-2 and pro-MMP-9 production in RASFC (i) and RA
synovial tissue (ii) following 24 h stimulation with Pam3CSK4 (1 μg/ml) (n = 3). Data is represented as mean ± SEM, *p <0.05, **p <0.01, significantly different
to control. HMVEC human microvascular endothelial cells, MMP matrix metalloproteinase, RA rheumatoid arthritis, RASFC rheumatoid arthritis
synovial fibroblast cells, TIMP tissue inhibitor of metalloproteinase
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To further assess the role of TLR2, we cultured ex vivo RA
whole tissue synovial explants embedded in matrigel
for 15 days with Pam3CSK4 (1 μg/ml). Images of RA
synovial outgrowths are shown in Fig. 3b where a signifi-
cant increase in synovial outgrowth is demonstrated in
response to Pam3CSK4 compared to basal control (indi-
cated by black arrows) where minimal outgrowth wasobserved. Pam3CSK4 significantly increased expression of
β1-integrin on the cell surface of RASFC (p <0.05) (Fig. 3c).
No significant differences were observed in the levels of β2,
β3, β4, β6, αVβ5 or α5β1 integrins. Figure 3d demonstrates
a 2.6- ± 0.66 fold increase in β1-integrin mRNA following
Pam3CSK4 stimulation. Furthermore Pam3CSK4 induced
active Rac1 compared to basal control in RASFC, without
change in global Rac1 expression (Fig. 3e). Figure 3f shows
Fig. 3 Representative photomicrograph showing cytoskeletal rearrangement of RASFC (a) and ex vivo synovial explant culture matrigel assays (b)
in response to Pam3CSK4 (1 μg/ml). Pam3CSK4 induces cytoskeletal rearrangement in RASFC (iv–vi) compared to basal control (i–iii) as evidenced
by loss of F-actin fibres (green) and formation of filopodial and lamellopodial protrusions (red arrows) (n = 3). Original magnification x60 (i, ii, iv, v)
or x40 (iii, vi). (b) Pam3CSK4 (1 μg/ml) also induces synovial outgrowths from ex vivo RA explants as indicated by black arrow (right panel) compared to
basal (left panel) (n = 3). c Bar graph quantifying beta integrin increased expression of β1-integrin on the cell surface of RASFC treated with
Pam3CSK4 (1 μg/ml) (n = 5). d Bar graph representing β1-integrin mRNA in RASFC under basal conditions or stimulated with Pam3CSK4
(1 μg/ml) (n = 5). e Representative Western blot for activated Rac1, total Rac1 and β-actin control in RASFC following 24 h stimulation with
Pam3CSK4 (1 μg/ml). f Densitometry quantification of active Rac1 in RASFC (n = 3). Data is represented as mean ± SEM, *p <0.05, significantly different to
control. RA rheumatoid arthritis, RASFC rheumatoid arthritis synovial fibroblast cells
McGarry et al. Arthritis Research & Therapy  (2015) 17:153 Page 7 of 14representative bar graph demonstrating a 4.2-fold increase
in active Rac1 in response to Pam3CSK4.β1-integrin is expressed in RA synovial tissue
Representative histological images demonstrate increased
β1-integrin expression in RA synovial tissue compared
to healthy control synovium (Fig. 4a). β1-integrin is
highly expressed around the vasculature, in the synovial
lining layer and also in the sub-lining layer of RA syn-
ovial tissue, as indicated by black arrows (Fig. 4a, upper
panels). In contrast, β1-integrin expression in normal
synovial tissue is minimal. No staining was observed for
IgG control (Fig. 4a, lower left panel). Semi-quantification
showed increased expression of β1-integrin in RA versus
healthy control (HC) tissue for the perivascular/vascular
regions (2.9 ± 0.34 vs 0.4 ± 0.16; p <0.005) sub-lining(1.5 ± 0.29 vs 0.3 ± 0.12, p <0.005), and lining layer (1.9 ±
0.32 vs 0.3 ± 012, p <0.005) (Fig. 4b).
Pam3CSK4-induced cell migration and invasion is
mediated through β1-integrin
To examine if Pam3CSK4-induced migration and in-
vasion processes are in part mediated by the β1-
integrin signalling pathways, RASFC and HMVEC
were stimulated with Pam3CSK4 in the presence or
absence of neutralizing antibody against β1-integrin or
an isotype-matched anti-IgG control. Figure 5a dem-
onstrates Pam3CSK4-induced RASFC and HMVEC
migration was inhibited in the presence of anti-β1-
integrin. Representative images of RASFC are shown
in Fig. 5a (i). Semi-quantitative analysis demonstrated
a significant decrease in Pam3CSK4-induced cell mi-
gration in response to anti-β1-integrin in both RASFC
Fig. 4 a Representative photomicrographs of immunohistochemical
staining of β1-integrin expression in RA and normal synovial tissue.
β1-integrin expression in RA synovial sections was localised to lining
layer, sub-lining and vascular regions as indicated by black arrows.
Representative images of β1-integrin minimal staining in healthy
control (HC) tissue with no staining observed for IgG control. The
scale bar (lower right-hand corner) represents a distance of 50 μm.
b Representative bar graphs demonstrating increased β1-integrin
expression in RA synovium, lining layer, sub-lining layer, peri-vasulature
regions compared HC synovium. Data is represented as mean ±
SEM, *p <0.05, **p <0.01, ***p <0.005, significantly different to control. IgG
immunoglobulin G, RA rheumatoid arthritis
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Pam3CSK4-induced RASFC invasion was inhibited in
the presence of anti-β1-integrin (p <0.05), with no ef-
fect observed for the IgG control (Fig. 5b (i, ii)). Simi-
lar effects were observed for HMVEC (Figure S1A in
Additional file 1). Furthermore, Pam3CSK-induced
RASFC Rac1 activation was inhibited by anti-β1-
integrin in RASFC, with no change in global Rac1 ex-
pression (Fig. 5c; Figure S1B in Additional file 1).
Interestingly, anti-β1-integrin had no effect on
Pam3CSK4-induced MMP-3 (p = 0.87) (data not
shown), suggesting that these were independent of β1-
integrin.OPN301 inhibits migration and invasion RA explants and
RASFC
To further examine the therapeutic potential of blocking
these pathways we assessed the effect of an anti-TLR2
antibody OPN301 in the ex vivo RA synovial explant
model. OPN301 significantly reduced spontaneous se-
cretion of MMP-3 from the RA explants compared to
IgG control (p <0.05) (Fig. 6a (i)), resulting in a signifi-
cant reduction in the MMP-3:TIMP-3 ratio (Fig. 6a (iii))
(p <0.05), thus favouring an MMP/TIMP balance against
joint destruction. This was also reflected in the expres-
sion of MMP-2 and MMP-9 both of which were inhib-
ited in the presence of OPN301 (Fig. 6b, lane 2)
compared to IgG control (Fig. 6b, lane one). OPN301 re-
duced MMP-1 secretion from explants but this did not
reach significance (Figure S1C in Additional file 1).
RASFC wounded monolayers were cultured with condi-
tioned media from RA synovial explants treated with
OPN301 or IgG control. OPN301-conditioned media
inhibited RASFC cell migration across the wound, in
contrast to those cultured with IgG control-conditioned
media, which had no inhibitory effect (Fig. 6c). Finally,
Fig. 6d demonstrates OPN301-conditioned media also
inhibited RASFC invasion through a matrigel compared
to IgG control. Figure 6d (ii) shows a representative bar
graph demonstrating a decreased number of invading
RASFC following incubation with OPN301-conditioned
media.
Discussion
RA is a chronic inflammatory disease characterised by
increased angiogenesis, cell migration and synovial
hyperplasia. TLR2 has been implicated in the pathogen-
esis of RA, however, the functional mechanisms and
signalling pathways mediating its effect on synovial migra-
tion and invasion have not been extensively investigated. In
this study, we demonstrate that TLR2 activation induces
RASFC and HMVEC cell migration, invasion, RA synovial
explant outgrowths, in addition to an increase in MMP
production. Furthermore, we show that TLR2-induced mi-
gration/invasion is partly mediated by β1-integrin and
downstream alterations in cytoskeletal dynamics and Rac1
activation. Finally, using an ex vivo RA synovial explant
model and RASFC, we demonstrated that blockade of
TLR2 significantly inhibited MMP secretion, RASFC mi-
gration and invasion.
There is increasing evidence that TLR2 activation
plays a critical role in the pathogenesis of RA [6, 26, 27].
Previous studies have demonstrated increased expression
of TLR2 in synovial cells and tissue, [4, 5] and shown
that TLR2 blockade significantly inhibited spontaneous
secretion of pro-inflammatory cytokines from RA syn-
ovial explant cultures, an effect similar to that of tumour
necrosis factor alpha (TNF-α) inhibitors [22]. In this
Fig. 5 a Representative photomicrographs of RASFC inhibition of migration by anti-β1-integrin (10 μg/ml) are seen in (i). Bar graphs showing RASFC (ii) and
HMVEC (iii) repopulating the wound in response to Pam3CSK4 (1 μg/ml), an effect that is inhibited by anti-β1-integrin (10 μg/ml) (n = 4). b Representative
photomicrographs showing anti-β1-integrin (10 μg/ml) inhibits Pam3CSK4 (1 μg/ml)-induced RASFC invasion (i). Bar graph quantifying RASFC invasion (ii)
(n = 4). cWestern blot for Rac1, total Rac1 and β-actin control demonstrating that Pam3CSK4 (1 μg/ml)-induced Rac1 activation in RASFC is inhibited by the
presence of anti-β1-integrin (10 μg/ml), with no effect observed for anti-IgG control monoclonal antibody (10 μg/ml). Total Rac1 was unchanged (n = 1) Data
is represented as mean ± SEM, *p <0.05, **p <0.01, significantly different to control. HMVEC human microvascular endothelial cells, IgG immunoglobulin G,
RASFC rheumatoid arthritis synovial fibroblast cells
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Fig. 6 a Quantification of RA synovial tissue spontaneous secretion of MMP-3 (i), TIMP-3 (ii) and the MMP-3/TIMP-3 ratio (iii) following culture with
OPN301 (1 μg/ml) or IgG control (1 μg/ml) (n = 4). b Decreased MMP-2 and MMP-9 expression in response to culture with OPN301 (1 μg/ml)
compared to anti-IgG control antibody (1 μg/ml) in RA synovial culture supernatants as assessed by gelatin zymography (n = 3) (c). Representative
photomicrograph demonstrating inhibition of RASFC migration in response to conditioned media from ex vivo RA synovial tissue treated with
OPN301 (1 μg/ml) compared to IgG control (1 μg/ml) (n = 3) (d). Representative photomicrographs showing OPN301-conditioned media (1 μg/ml) inhibits
RASFC invasion compared to IgG-conditioned media (i). Bar graph quantifying RASFC invasion (ii) (n = 4). Data is represented as mean ± SEM,
*p <0.05, significantly different from control. IgG immunoglobulin G, MMP matrix metalloproteinase, RA rheumatoid arthritis, RASFC rheumatoid
arthritis synovial fibroblast cells, TIMP tissue inhibitor of metalloproteinase
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HMVEC migration and invasion processes, and induces
synovial RASFC outgrowth, indicative of the invasive
process in RA. Supporting our data, previous studies
have demonstrated that TLR2 can induce angiogenic
factors and chemokines such as vascular endothelial
growth factor (VEGF) and interleukin 8 (IL-8)-promot-
ing cell migrational and angiogenic processes in fibro-
blasts, chondrocytes, corneal epithelial cells and THP-1
macrophages [28, 29]. Granulocyte-macrophage colony-
stimulating factor (GM-CSF) mediates the effect of
TLR2/6 agonist, macrophage-activating lipopeptide of 2
kDa (MALP-2) on angiogenic tube formation and leuco-
cytes migration in vivo and in vitro [30]. Furthermore in
RASFC, PG activation induces intercellular adhesion
molecule (ICAM)-1, interleukin 6 (IL-6) and IL-8 [31].
In addition, Saber et al. 2011, demonstrated in RASFC
and RA explant cultures that TLR2 activation induces
angiogenic tube formation, adhesion molecule expres-
sion and growth factor expression, an effect that was in
part mediated through the angiopoietin 2 (Ang2)/Tie-2
pathway [11].
The induction of MMP-3 by TLR2 in RASFC is con-
sistent with a study by Yokota et al. showing TLR2 can
synergise with NOD1 in the induction of MMP-3 in
RASFC [9]. In addition, a recent study demonstrated
that microRNA-19a/b can regulate MMP-3 secretion
through activation of TLR2 [10]. Previous studies haveshown that MMP-1 and MMP-3 correlate with erosive
progression in RA [32]. In addition, studies have shown
an association between MMP-3, cartilage neoepitopes,
and serum amyloid A (SAA) [33] and demonstrated that
MMP-3 levels at baseline predict radiographic progression
following TNF-α inhibitor (TNFi) therapy [32]. Fur-
thermore, in human periodontal fibroblasts, TLR2 acti-
vation can induce MMP-1 and MMP-3 via p38, JNK
and NF-ĸB [34].
We also demonstrated a significant shift in both the
MMP-3/TIMP-3 and MMP-1/TIMP-3 ratios suggesting
TLR2 activation in the RA joint favours destructive path-
ways. TLR2 activation inhibited TIMP-3 in RA synovial ex-
plants but not RASFC. The expression of TIMP-3 in RA
synovial tissue lysates has been previously reported, how-
ever, studies did not identify the cellular source of TIMP-3
and the majority of studies in RA only focus on the expres-
sion of TIMP-3 in RASFC. However, studies in different
disease states and mouse models have demonstrated ex-
pression of TIMP-3 in endothelial cells [35], chondrocytes
[36] and macrophages [37]. As endothelial cells and macro-
phages are two prominent cell types in the RA synovium,
this suggests that they may be a potential source of the
TIMP-3 secreted from explants in response to TLR2
activation.
To further probe the precise mechanisms involved in
mediating TLR2-induced synovial invasion, we investi-
gated the role of the β1-integrin signalling pathway. We
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duced β1-integrin binding with no effect observed for
β2, β3, β4, β6, αVβ5 or α5β1. Further downstream, we
showed that Pam3CSK4-induced Rac1 activation, which
is critical for cell actin assembly at the cell periphery
promoting cell movement. The effect of TLR2 on
β1-integrin and Rac1 was parallelled by alteration in
cytoskeletal dynamics where a dramatic effect on the
cytoskeletal integrity was observed in both RASFC and
HMVEC, consistent with the localised expression of
β1-integrin in RA synovial tissue. Finally, we demon-
strated that β1-integrin mediated TLR2 function in
RASFC and HMVEC, by showing that TLR2-induced
migrational and invasive processes were inhibited by
neutralising antibodies against β1-integrin.
This is the first study to demonstrate that the
β1-integrin pathways specifically mediates TLR2-induced
invasion in the inflamed joint, with minimal effect ob-
served for other β-integrins. This is consistent with previ-
ous studies showing β-integrin expression on RASFC is
associated with their enhanced binding to extracellular
matrix (ECM) [38]. The β1-integrin receptor plays a key
role in the attachment of RASFC to ECM components
and the subsequent invasion of cartilage [18, 38] and can
induce Rho GTPases, specifically Rac1 in chondrocytes
and murine macrophages [39, 40]. Integrin receptors,
p-focal adhesion kinase (FAK) and p-paxillin are signifi-
cantly increased in RA synovial tissue [41]. β1-integrin is
known to be involved in angiogenesis and in the response
of T cells to fibronectin-induced chemotactic signals
[39, 42]. While little is known about the cross-talk be-
tween TLR2 and integrin-FAK-mediated pathways in
the RA synovium, previous studies have reported that
TLR2 mediates macrophage cytoskeletal rearrangement,
promoting macrophage spreading and polarisation, a
process required during extravasation and migration [43].
Furthermore, studies have also reported that TLR2 activa-
tion induces angiogenesis and EC migration in response
to oxidative stress via Rac1 [44, 45] and TLR2(−/−) and
MyD88(−/−) macrophages have impaired Rac1 and PI3K
function [46].
The mechanisms by which TLR2 mediates β1-integrin
action remains unclear. β1-integrin is a transmembrane
receptor that is a bridge for cell–cell and cell–ECM interac-
tions, which in turn activates the cytoskeletal dynamics.
Ligands for β1-integrin include fibronectin, vitronectin, col-
lagen, and laminin. While no studies in RA cells have
shown a direct link between TLR2 and these ligands, a few
studies in other disease cells have shown that TLR2 and 4
can regulate the expression of different ECM proteins.
Vitronectin and fibronectin have been shown to be essential
for TLR2-mediated processes in vitro, both of which are
known to be induced in RA [47–51]. Furthermore, while
no studies have yet shown a direct link between TLR2 andβ1-integrin, we and others have shown that TLR2 is a
functional receptor for acute-phase (A)-SAA, which is
known to induce cell migration through integrin–
cytoskeletal-mediated pathways in the joint [33, 52].
Previous studies have also shown interactions between
A-SAA and ECM glycosaminoglycans, and with lam-
inin and vitronectin-induced adhesion and migration
in a β1-integrin-dependent manner [53, 54].
In this study, β1-integrin blockade had no effect on
MMP-3 expression in RASFC. β1-integrin blockade is
required to block MMP-2 activation induced by collagen
I (Col I) [55]. Other studies have demonstrated in mice
lacking α2β1 integrin, inhibition of MMP-3 expression
in RASFC and cartilage degradation [18]. MMP can in
turn regulate integrins, with studies showing the regula-
tory action of MMP-13 on α11β1-dependent matrix
remodelling in fibroblasts [56]. However, a study by
Ozeki et al., demonstrated complimentary but independ-
ent action of α2 integrin and MMP-3-mediated signalling
cascades in driving mouse embryonic stem cell differenti-
ation into odontoblast-like cells [57]. Interactions between
integrins and MMP in the regulation of matrix remodel-
ling thus may be complimentary and bi-directional with
differential sensitivity and activation mechanisms in differ-
ent cell types or tissues [58].
Finally, we used an ex vivo RA synovial tissue (ST) ex-
plant model to investigate the role of TLR2 blockade on
RA synovial invasion. This model maintains the cell–cell
contact of the complex mix of different cell types whose
interaction contributes to the pro-inflammatory environ-
ment in the RA joint. RA synovial explants spontaneously
release key pro-inflammatory mediators and therefore are
ideal for examining potential therapeutic molecules. We
demonstrated that OPN301 inhibited spontaneous secre-
tion of MMP-3, MMP-2, and MMP-9 and inhibited the
MMP3/TIMP3 ratio in favour of decreased cartilage deg-
radation. We also demonstrated that OPN301-conditioned
media inhibited RASFC migration and invasion, suggesting
OPN301 inhibited spontaneous release of soluble mediators
that are involved in migratory and invasive mechanisms in
the RA joint. When RASFC were cultured with OPN301
and IgG alone no inhibitory effect on RASFC migration in
response to OPN301 was observed (Figure S1D in
Additional file 1). This further suggests endogenous
TLR2 ligands are present in the inflamed joint. However, as
OPN301 had no direct effect on RASFC migration, ligands
may be secreted by other cells in RA synovial tissue. While
no ligand has been defined, the existence of a ligand is sup-
ported by studies which showed that macrophages were ac-
tivated in a MyD88 and Mal-dependent manner when
cultured with conditioned media from RA synovial explants
[8]. Several potential ligands have been suggested such as fi-
bronectin fragments, heat shock protein 70, hyaluronidase
oligosaccharides, high mobility group protein 1 (HMBG-1)
McGarry et al. Arthritis Research & Therapy  (2015) 17:153 Page 12 of 14and glycoprotein 96 (GP96) all of which have been identi-
fied in the RA joint [59–63]. These studies support our data
suggesting the presence of TLR2 ligands actively secreted
from RA ex vivo synovial tissue.
Conclusions
In conclusion, we demonstrate that activation of TLR2 in-
duces RASFC migration, invasion and extracellular matrix
breakdown, through induction of MMPs. We show that
TLR2-induced migration/invasion is partly mediated by
β1-integrin and downstream alterations in cytoskeletal
dynamics. Finally, using an ex vivo RA synovial explant
model, we demonstrate that TLR2 blockade significantly in-
hibits MMP expression and migration, suggesting the pres-
ence of an endogenous ligand. This study further supports
that hypothesis that TLR2-induced signalling pathways are
involved in the pathogenesis of RA.
Additional file
Additional file 1: Figure S1. (A) Representative photomicrographs
showing anti-β1-integrin (10 μg/ml) inhibits Pam3CSK4 (1 μg/ml)-induced
HMVEC invasion (i). Bar graph quantifying HMVEC invasion (ii) (n = 4). (B)
Densitometry quantification of RASFC Pam3CSK4 (1 μg/ml)-induced active
Rac1 inhibited in the presence of anti-β1 (10 μg/ml). Data is expressed as fold
change compared to β-actin control (n = 1) (C) Quantification of RA synovial
tissue spontaneous secretion of MMP-1 following culture with OPN301
(1 μg/ml) or IgG control (1 μg/ml) (n = 4). (D) Representative photomicrograph
demonstrating no change in RASFC migration in OPN301 (1 μg/ml)-treated
cells compared to IgG control (1 μg/ml) (n = 3).
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